Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED)
Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED)
In February 2002, a French Consensus Conference on the management of patients with chronic
 hepatitis C in France was organized. The jury issued several recommendations on pegylated
 alpha interferon/ribavirin treatment strategy. Three years after these recommendations, it is
 of interest to understand the evolution of hepatitis C management in France in real clinical
 practice. This observational study will permit the identification of patients who are treated
 and will provide information on the use of PegIntron/ Ribavirin.
To assure a good representation of participants treated for hepatitis C, participants who
 meet the inclusion criteria will be enrolled on a consecutive basis.
Inclusion Criteria:

 -  Adult participants starting a treatment with PegIntron for the treatment of chronic
 hepatitis C.

 Exclusion Criteria:

 -  Concomitant participation in a clinical trial for the treatment of hepatitis C.